At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 135 enrolled
Drug / intervention
1g of F373280 +1 moredrug
Likely dose
1g of F373280from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Study of F373280 for Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation and Chronic Heart Failure. International, Multicentric, Randomised, Double-blind, Placebo Controlled Study.
In Brief
A Phase 2 clinical trial evaluating 1g of F373280 and Placebo for Atrial Fibrillation. Completed, enrolled 135 participants across 20 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess the efficacy of F373280 on the maintenance of normal cardiac rhythm after direct electric cardioversion in patients with persistent atrial fibrillation and cardiac failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesCzechia, Hungary, Italy, Poland, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedApr 2013
Primary CompletionApr 2017
Study CompletionJun 2017
TodayJul 2026
First PostedApr 15, 2013
Enrollment StartApr 1, 2013
Primary CompletionApr 3, 2017
Study CompletionJun 21, 2017
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 13.2 years ago
Interventions
1g of F373280drug
Oral administration, one capsule each evening with dinner.
Placebodrug
Oral administration, one capsule each evening with dinner.